Elective nodal radiotherapy with a gapless radiation field junction for oligorecurrent prostate cancer after previous radiotherapy

被引:0
|
作者
Li, Minglun [1 ]
Fan, Yourong [1 ]
Trapp, Christian [1 ]
Schmidt-Hegemann, Nina Sophie [1 ]
Ma, Jing [1 ]
Buchner, Alexander [1 ]
Lu, Shun [1 ]
Xu, Bin [1 ]
Stief, Christian [1 ]
Wang, Xuanbin [1 ]
Zhou, Cheng [1 ]
Belka, Claus [1 ]
Rogowski, Paul [1 ]
机构
[1] Ludwig Maximilians Univ LMU, Univ Hosp Munich, Munich, Germany
关键词
ENRT; Nodal oligorecurrence; Gapless radiation field junction; Reirradiation; PSMA-PET; CT; RADICAL PROSTATECTOMY; SALVAGE RADIOTHERAPY; THERAPY; TOXICITY; PATTERNS; REIRRADIATION; RECURRENCE; FAILURE;
D O I
10.1016/j.ctro.2022.100571
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the feasibility of subsequent elective nodal radiotherapy (ENRT) for nodal recurrences after previous radiotherapy with a defined planning approach for a gapless radiation field junction.Methods: Patients with 1) previous radiotherapy of prostate or prostatic fossa and subsequent pelvic ENRT or 2) previous pelvic radiotherapy and subsequent ENRT to paraaortic lymph nodes (LN) and gapless junction of both radiation fields were analyzed. The cumulative maximum dose (Dmax-cum) and the maximum cumulative dose in 1 cc (D1cc-cum) were estimated. Absolute toxicity and the toxicity exceeding baseline were evaluated.Results: Twenty-two patients with PSMA-PET/CT-staged nodal oligorecurrence after prior radiotherapy were treated with pelvic (14 patients) or paraaortic ENRT (9 patients). One patient was treated sequentially at both locations. Median time between first and second RT was 20.2 months. Median doses to the lymphatic pathways and to PET-positive LN were 47.5 Gy and 64.8 Gy, respectively. The planning constraint of an estimated Dmax-cum < 95 Gy and of D1cc-cum < 90 Gy were achieved in 23/23 cases and 22/23 cases, respectively. Median follow-up was 33.5 months. There was no additional acute or late toxicity >= grade 3. Worst acute toxicity exceeding baseline was grade 1 in 68.2% and grade 2 in 22.7% of patients. Worst late toxicity exceeding baseline was grade 1 in 31.8% and grade 2 in 18.2% of patients.Conclusion: ENRT for nodal recurrences after a previous radiotherapy with gapless junction of radiation fields seems to be feasible, applying the dose constraints Dmax-cum < 95 Gy and D1cc-cum < 90 Gy without grade 3 acute or late toxicities exceeding baseline.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] STEREOTACTIC RADIOTHERAPY FOR ISOLATED NODAL RECURRENCE OF PROSTATE CANCER
    Loi, Mauro
    Trombetta, Laura
    Olmetto, Emanuela
    Topulli, Juliana
    Francolini, Giulio
    Giacomelli, Irene
    Becherini, Carlotta
    Grassi, Roberta
    Detti, Beatrice
    Baldazzi, Valentina
    Livi, Lorenzo
    ANTICANCER RESEARCH, 2016, 36 (05) : 2583 - 2583
  • [32] Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 143 - 151
  • [33] Nodal recurrence patterns on PET/CT after RTOG-based nodal radiotherapy for prostate cancer
    Liskamp, C. P.
    Donswijk, M. L.
    van der Poel, H. G.
    Schaake, E. E.
    Vogel, W. V.
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2020, 22 : 9 - 14
  • [34] Elective neck dissection for second primary after previous definitive radiotherapy
    Falchook, Aaron D.
    Dagan, Roi
    Morris, Christopher G.
    Mendenhall, William M.
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2012, 33 (02) : 199 - 204
  • [35] Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
    Christoph Henkenberens
    Ann-Kathrin Oehus
    Thorsten Derlin
    Frank Bengel
    Tobias L. Ross
    Markus A. Kuczyk
    Stefan Janssen
    Hans Christiansen
    Christoph A. J. von Klot
    Strahlentherapie und Onkologie, 2020, 196 : 1006 - 1017
  • [36] Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
    Henkenberens, Christoph
    Oehus, Ann-Kathrin
    Derlin, Thorsten
    Bengel, Frank
    Ross, Tobias L.
    Kuczyk, Markus A.
    Janssen, Stefan
    Christiansen, Hans
    von Klot, Christoph A. J.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (11) : 1006 - 1017
  • [37] The role of elective nodal irradiation in radiotherapy for stage I esophageal cancer
    Tsuruoka, S.
    Kataoka, M.
    Makita, K.
    Ishikawa, H.
    Takada, N.
    Nagasaki, K.
    Hamamoto, Y.
    Mochizuki, T.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S780 - S780
  • [38] SKIN METASTASES WITHIN THE PREVIOUS RADIATION-FIELD AFTER PROPHYLACTIC POSTOPERATIVE RADIOTHERAPY FOR BREAST-CANCER
    ITO, H
    KUBO, A
    SHIGEMATSU, N
    HASHIMOTO, S
    CLINICAL & EXPERIMENTAL METASTASIS, 1984, 2 (03) : 235 - 239
  • [39] Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences
    Ost, P.
    Jereczek-Fossa, B. A.
    Van As, N.
    Zilli, T.
    Tree, A.
    Henderson, D.
    Orecchia, R.
    Casamassima, F.
    Surgo, A.
    Miralbell, R.
    De Meerleer, G.
    CLINICAL ONCOLOGY, 2016, 28 (09) : E115 - E120
  • [40] PSMA-PET guided stereotactic body radiotherapy for bone oligorecurrent prostate cancer
    Cuccia, F.
    Mazzola, R.
    Pastorello, E.
    Ingrosso, G.
    Franzese, C.
    Scorsetti, M.
    Figlia, V.
    Giaj-Levra, N.
    Nicosia, L.
    Rigo, M.
    Ricchetti, F.
    Vitale, C.
    Attina, G.
    Ruggieri, R.
    Alongi, F.
    RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S61 - S62